Scientists crack the code behind stem cell vesicles' anti-inflammatory power

A team of researchers has uncovered a key mechanism behind the anti-inflammatory effects of extracellular vesicles derived from mesenchymal stromal cells. The discovery, led by the IVECAT group at IGTP, highlights how surface N-glycosylation plays a critical role in their ability to reduce inflammation. Their findings have been published in the Journal of Extracellular Vesicles. The study involved a multidisciplinary effort, combining advanced imaging technologies with detailed mechanistic analysis. Researchers used an in vitro dynamic flow system to mimic the vascular environment, allowing them to observe how MSC-derived EVs interact with inflamed endothelial cells under realistic conditions.

They found that intact N-glycosylation on the vesicle surface is essential for their uptake and function. Without it, the vesicles lost their ability to inhibit monocyte recruitment to inflamed endothelial cells. This process is mediated through the MCP-1/CCR2 chemokine axis, a pathway known to drive immune cell infiltration in inflammatory and ischemic conditions.

The team also demonstrated that surface glycosylation patterns determine how well the vesicles target and modulate immune responses. This insight suggests new ways to engineer vesicles with specific glycan signatures for therapeutic use. The study sheds light on how MSC-derived EVs can reduce monocyte extravasation across inflamed tissues, offering a potential therapeutic strategy. By targeting the CCR2-driven recruitment mechanism, future treatments could limit excessive immune cell infiltration and tissue damage. The research advances the development of engineered vesicles for treating inflammatory and ischemic diseases.